$RVVTF for those more knowledgeable about the bucillamine for Covid trial than I, help me out. Some quick research indicates that the fda recommended going straight to phase 3, I’m guessing because the safety profile was known to be good. Has there been any preclinical or in vitro data? Has there been any efficacy data released from the trial? I couldn’t find any in my brief search. I’m assuming that the optimism for the trial on the board is mainly coming from the DMC allowing the trial to continue? Because they’re evaluating safety and efficacy at every milestone correct? Are we assuming that if there was no benefit they would’ve halted the trial? Thanks, and if I missed something please correct me, looking for info here
1 Like